Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 48 for:    Recruiting, Not yet recruiting, Available Studies | "Carotid Stenosis"

" Endarterectomy Combined With Optimal Medical Therapy (OMT) vs OMT Alone in Patients With Asymptomatic Severe Atherosclerotic Carotid Artery Stenosis at Higher-than-average Risk of Ipsilateral Stroke " (ACTRIS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02841098
Recruitment Status : Not yet recruiting
First Posted : July 22, 2016
Last Update Posted : January 25, 2018
Sponsor:
Collaborator:
Hôpitaux Universitaires Paris Ile-de-Franc Ouest
Information provided by (Responsible Party):
Centre Hospitalier St Anne

Brief Summary:
The purpose of this study is to determine whether carotid surgery combined with optimal medical therapy improves long-term survival free of ipsilateral stroke in patients with asymptomatic carotid stenosis at higher-than-average risk of ipsilateral stroke when compared with optimal medical therapy alone.

Condition or disease Intervention/treatment Phase
Asymptomatic Carotid Artery Stenosis Other: Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT) Drug: Optimal medical therapy alone Phase 3

Detailed Description:

Carotid artery stenosis >= 50% affects about 3% of subjects >= 60 years and accounts for up to 15% of all ischemic strokes. Overall, patients with asymptomatic carotid stenosis have a low risk of ipsilateral stroke on modern medical therapy. It is therefore uncertain whether the benefit of carotid surgery still justifies the perioperative risk of stroke or death, and whether revascularisation is good value for money considering competing demands on health services. Several imaging techniques have been developed to identify patients with asymptomatic carotid stenosis at higher-than-average risk of ipsilateral stroke. Specifically, the presence of transcranial Doppler (TCD)-detected embolic signals, intraplaque haemorrhage on magnetic resonance imaging, TCD-measured impaired cerebral vasomotor reserve or rapid stenosis progression have all been shown to involve an at least 3-fold higher risk of ipsilateral stroke. However, before recommendations for clinical practice can be made regarding the use of these tools, their utility must be demonstrated in a formal randomised clinical trial. Our hypothesis is that the use of these predictors can identify a subset of patients with asymptomatic carotid stenosis who could benefit from prophylactic endarterectomy.

Carotid endarterectomy The procedure will be carried out with the technique routinely used by each surgeon. Operative reports and perioperative complications will be collected. CEA will have to be performed as soon as possible, within 60 days after randomization.

Optimal medical therapy OMT will be applied to all patients and started immediately after randomisation.

OMT will be defined by the adhoc committee and follow relevant guidelines. It will include:

  • Antiplatelet therapy. If the patient requires anticoagulation for any reason (e.g. atrial fibrillation), the patient should be treated with an appropriate anticoagulant according to the practice at the centre as an alternative to antiplatelet therapy.
  • Antihypertensive treatment, if required, to achieve a target blood pressure < 140/90 mmHg (higher targets may be defined by the OMT committee for selected conditions, e.g. contralateral carotid occlusion) Application of structured programs, such as stepped-care approach using ranking of antihypertensive drugs will be used.
  • High-dose statin treatment (target LDL < 0.7 g/l). A stepped-care approach with raking of lipid-lowering drugs will also be used.
  • Patients smoking at the time of randomisation will be encouraged to stop and join a smoking cessation and support program.
  • Other lifestyle modification: reduction of alcohol consumption, choosing healthy food, increasing regular physical activity, reduction of body weight if relevant.

OMT may be modified during the course of the trial to take account revised guidelines or new evidence.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 700 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: " Endarterectomy Combined With Optimal Medical Therapy Versus Optimal Medical Therapy Alone in Patients With Asymptomatic Severe Atherosclerotic Carotid Artery Stenosis at Higher-than-average Risk of Ipsilateral Stroke "
Estimated Study Start Date : April 2018
Estimated Primary Completion Date : September 2024
Estimated Study Completion Date : December 2024

Arm Intervention/treatment
Experimental: Carotid endarterectomy combined with optimal medical therapy
Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT)
Other: Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT)
Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT) (Surgery and Drug)

Active Comparator: Optimal medical therapy (OMT)
Optimal medical therapy (OMT)
Drug: Optimal medical therapy alone
Optimal medical therapy alone




Primary Outcome Measures :
  1. Ipsilateral stroke or procedural stroke or death [ Time Frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72 ]
    Any ipsilateral stroke within 6 years after randomization or procedural (within 30 days after revascularization) stroke or death


Secondary Outcome Measures :
  1. Any stroke or procedural death [ Time Frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72 ]
    Any stroke within 6 years after randomization or procedural death (within 30 days after revascularization)

  2. Any disabling or fatal stroke or procedural death [ Time Frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72 ]
    Any disabling or fatal stroke within 6 years after randomization or procedural death (within 30 days after revascularization)

  3. Any stroke or TIA or procedural death [ Time Frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72 ]
    Any stroke or TIA within 6 years after randomization or procedural death within 6 years after randomization

  4. Any stroke or death [ Time Frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72 ]
    Any stroke or death within 6 years after randomization

  5. Myocardial infarction [ Time Frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72 ]
    Myocardial infarction within 6 years after randomization

  6. Any death [ Time Frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72 ]
    Any death within 6 years after randomization

  7. Cardiovascular death [ Time Frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72 ]
    Cardiovascular death within 6 years after randomization

  8. Any hospitalisation for vascular disease [ Time Frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72 ]
    Any hospitalisation for vascular disease within 6 years after randomization

  9. Cranial nerve palsy attributed to revascularisation [ Time Frame: M1 ]
    Cranial nerve palsy attributed to revascularisation within 30 days after revascularization

  10. Haematoma caused by treatment requiring surgery, transfusion or prolonging hospital stay [ Time Frame: M1 ]
    Haematoma caused by treatment requiring surgery, transfusion or prolonging hospital stay within 30 days after revascularization

  11. Further revascularisation of the randomised artery after the initial attempt. [ Time Frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72 ]
    Further revascularisation of the randomised artery after the initial attempt.

  12. Carotid revascularisation [ Time Frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72 ]
    Carotid revascularisation during follow-up other than that allocated at randomisation

  13. New cerebral infarction or haemorrhage [ Time Frame: M24 ]
    New cerebral infarction or haemorrhage on MRI at 2 years

  14. Increase in white-matter changes [ Time Frame: M0, M24 ]
    Increase in white-matter changes on MRI at 2 years.

  15. Cognitive impairment [ Time Frame: M0, M24 ]
    Cognitive impairment assessed by the Montreal Cognitive Assessment (MoCA) with adjustment for demographic factors.

  16. Depression [ Time Frame: M0, M24 ]
    Depression measured by the Centre for Epidemiologic Studies Depression (CES-D) Scale.

  17. Health-related quality of life [ Time Frame: M0, M24 ]
    Health-related quality of life measured using the European Quality Of Life (EQ-5D).

  18. Disability [ Time Frame: M0, M24 ]
    Disability measured by the modified Rankin scale with structured interview

  19. Achievement of goals for each of the components of optimal medical treatment [ Time Frame: M1, M6, M12, M18, M24, M30, M36, M42, M48, M54, M60, M66, M72 ]
    Achievement of goals for each of the components of optimal medical treatment



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 50 years or over
  • No ipsilateral stroke or TIA within 180 days of randomization
  • Atherosclerotic carotid stenosis between 60 and 99% (NASCET method)
  • At least one of the following markers of ipsilateral stroke risk:

    • TCD-detected microembolic signals
    • Impairment of TCD-measured cerebral vasomotor reserve
    • Intraplaque haemorrhage on magnetic resonance imaging
    • Rapid and severe stenosis progression
  • Patient is able and willing to give informed consent

Exclusion Criteria:

  • Previous revascularization procedure in the artery to be randomised
  • Patients not suitable for endarterectomy due to anatomical factors
  • Carotid stenosis caused by non-atherosclerotic disease e.g. neck radiotherapy or fibromuscular disease
  • Patients who have had contralateral carotid artery or vertebral artery or intracranial artery revascularisation within 6 weeks prior to randomisation
  • Patients with planned revascularisation of the contralateral carotid artery or a vertebral artery or an intracranial artery within 6 weeks after randomisation or the date of CEA
  • Patients who have had coronary artery bypass grafting within 3 months prior to randomisation or other major surgery within 6 weeks prior to randomisation
  • Patients with planned coronary artery bypass grafting or other major surgery within 6 weeks after CEA of the artery considered for treatment in the trial
  • Patients with pre-existing disability (modified Rankin score greater than 2)
  • Patients who have a low 5-year life expectancy (see appendix for definition)
  • Patients intolerant or allergic to all of the medications available for OMT
  • Patients in clinical trials of investigational medicinal products or who have been in clinical trials within the last 4 months will not be enrolled unless otherwise agreed
  • Patients who are known to be pregnant
  • Patients unwilling or unable to participate in follow-up

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02841098


Contacts
Layout table for location contacts
Contact: Jean-Louis MAS, MD 00 33 1 45 65 82 84 jl.mas@ch-sainte-anne.fr
Contact: Marie GODARD 00 33 1 45 65 77 28 marie.godard@aphp.fr

Locations
Layout table for location information
France
Centre Hospitalier régional de Besançon, Hôpital Jean Minjoz Not yet recruiting
Besançon, France, 25030
Contact: Thierry MOULIN, MD, PhD    00 33 3 81 66 84 38    thierry.moulin@univ-fcomte.fr   
CHU Bordeaux, Groupe Hospitalier Pellegrin Not yet recruiting
Bordeaux, France, 33076
Contact: Igor SIBON, MD, PhD    00 33 5 56 79 55 20    igor.sibon@chu-bordeaux.fr   
CHRU La Cavale Blanche Not yet recruiting
Brest, France, 29200
Contact: Serge TIMSIT, MD, PhD    00 33 2 98 34 73 00    serge.timsit@chu-brest.fr   
Hôpital Gabriel Montpied Not yet recruiting
Clermont-ferrand, France, 63003
Contact: Pierre CLAVELOU, MD, PhD    00 33 4 73 75 22 02    pclavelou@chu-clermontferrand.fr   
CHU Henri Mondor
Creteil, France, 94010
CHU Dijon-Bourgogne Not yet recruiting
Dijon, France, 21079
Contact: Maurice GIROUD, MD, PhD    00 33 3 80 29 37 53    maurice.giroud@chu-dijon.fr   
CHU de Grenoble Not yet recruiting
Grenoble, France, 38043
Contact: Olivier DETANTE, MD    00 33 4 76 76 57 89    odetante@chu-grenoble.fr   
Hôpital Mignot - CH Versailles Not yet recruiting
Le Chesnay, France, 78150
Contact: Fernando PICO, MD, PhD    00 33 1 39 63 95 17    fpico@ch-versailles.fr   
CHRU de Lille Not yet recruiting
Lille, France, 59037
Contact: Hilde HENON, MD    00 33 3 20 44 68 14    hilde.henon@chru-lille.fr   
Hôpital Neurologique Pierre Wertheimer GHE Not yet recruiting
Lyon, France, 69677
Contact: Norbert NIGHOGHOSSIAN, MD, PhD    00 33 4 72 35 78 10    Norbert.nighoghossian@chu-lyon.fr   
Hôpital Gui de Chauliac Not yet recruiting
Montpellier, France, 34 295
Contact: Caroline ARQUIZAN, MD    00 33 4 67 33 74 12    c-arquizan@chu-montpellier.fr   
CHU de Nice, Hôpital Pasteur 2 Not yet recruiting
Nice, France, 06000
Contact: Marie-Hélène MAHAGNE, MD    00 33 4 92 03 27 51    mahagne.h@chu-nice.fr   
Hôpital Lariboisière Not yet recruiting
Paris, France, 75010
Contact: Hugues CHABRIAT, MD, PhD    00 33 1 49 95 25 97    hugues.chabriat@aphp.fr   
Hôpital Saint-Antoine Not yet recruiting
Paris, France, 75012
Contact: Sonia ALAMOWITCH, MD, PhD    00 33 1 71 97 06 51    sonia.alamowitch@aphp.fr   
Groupe Hospitalier Pitié-Salpétrière Not yet recruiting
Paris, France, 75013
Contact: Yves SAMSON, MD, PhD    00 33 1 42 16 18 54    yves.samson@aphp.fr   
Centre Hospitalier Sainte-Anne Not yet recruiting
Paris, France, 75014
Contact: Jean-Louis MAS, MD, PhD    00 33 1 45 65 82 84    jl.mas@ch-sainte-anne.fr   
Centre Hospitalier Bichat-Claude Bernard Not yet recruiting
Paris, France, 75018
Contact: Pierre AMARENCO, MD, PhD    00 33 1 40 25 87 26    pierre.amarenco@aphp.fr   
CHU La Milétrie Not yet recruiting
Poitiers, France, 86021
Contact: Jean-Philippe NEAU, MD, PhD    00 33 5 49 44 44 46    jph.neau@chu-poitiers.fr   
Hôpital Pontchaillou CHU Rennes Not yet recruiting
Rennes, France, 35033
Contact: Jean-François PINEL, MD    00 33 2 99 28 42 93    jf.pinel@chu-rennes.fr   
CHU de Rouen, Hôpital Charles Nicolle Not yet recruiting
Rouen, France, 76031
Contact: Evelyne GUEGAN MASSARDIER, MD    00 33 2 32 88 67 86    evelyne.massardier@chu-rouen.fr   
Hôpital Nord CHU Saint-Etienne Not yet recruiting
Saint-etienne, France, 42055
Contact: Pierre GARNIER, MD    00 33 4 77 12 78 05    pierre.garnier@chu-st-etienne.fr   
CHU de Strasbourg, Hôpital de Hautpierre Not yet recruiting
Strasbourg, France, 67098
Contact: Valérie WOLFF, MD    00 33 3 88 12 86 06    valerie.wolff@chru-strasbourg.fr   
CHU de Toulouse Hôpital Pierre-Paul Riquet Not yet recruiting
Toulouse, France, 31059
Contact: Vincent LARRUE, MD, PhD    00 33 5 61 77 94 57    larrue.v@chu-toulouse.fr   
Sponsors and Collaborators
Centre Hospitalier St Anne
Hôpitaux Universitaires Paris Ile-de-Franc Ouest
Investigators
Layout table for investigator information
Study Director: Jean-Louis MAS CHSA

Layout table for additonal information
Responsible Party: Centre Hospitalier St Anne
ClinicalTrials.gov Identifier: NCT02841098     History of Changes
Other Study ID Numbers: D15-P010
First Posted: July 22, 2016    Key Record Dates
Last Update Posted: January 25, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Centre Hospitalier St Anne:
Carotid stenosis,stroke,endarterectomy,medical therapy

Additional relevant MeSH terms:
Layout table for MeSH terms
Carotid Stenosis
Constriction, Pathologic
Pathological Conditions, Anatomical
Carotid Artery Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases